Malignancy Risks With Biologic Therapies

John J. Cush, Kathryn H. Dao

Research output: Contribution to journalReview articlepeer-review

16 Scopus citations


The management of rheumatoid arthritis (RA) dramatically changed in 1998 with the introduction of etanercept and infliximab for the treatment of RA and Crohn colitis. Nine biologic agents are currently in use for treating RA. However, speculation has grown that the long-term use of these biopharmaceuticals may alter normal immunosurveillance, thereby contributing to an individual's cancer risk. Whether malignancy is a consequence of rheumatoid inflammation or the therapies used to treat RA has been unclear until recently. This article addresses the growing data on the short- and long-term cancer risks associated with biologic use in RA.

Original languageEnglish (US)
Pages (from-to)761-770
Number of pages10
JournalRheumatic Disease Clinics of North America
Issue number4
StatePublished - Nov 1 2012
Externally publishedYes


  • Biologic agent
  • Cancer
  • Rheumatoid arthritis
  • Tumor necrosis factor

ASJC Scopus subject areas

  • Rheumatology


Dive into the research topics of 'Malignancy Risks With Biologic Therapies'. Together they form a unique fingerprint.

Cite this